Document:

<PAGE>
                                                                   Exhibit 10.75

                            Retirement Allowance Plan
                                       for
                     Representative Directors and Directors
                                       of
                               Baldwin-Japan Ltd.

Article 1. Purpose.

     The purpose of this Retirement Allowance Plan is to govern, and provide
for, the retirement allowance of eligible Representative Directors and Directors
(reference herein to a "Director" shall include a Representative Director unless
the context requires otherwise) of the Company who are not otherwise covered by
the Company's work rules and retirement allowance program which apply to regular
employees (the "Employee Plan").

Article 2. Eligibility.

     A Director of the Company who is appointed and works for the Company on a
full-time basis and who is not otherwise covered by the Employee Plan shall be
automatically eligible to participate in this Retirement Allowance Plan. A
Director of the Company who is not a full-time officer of the Company or who is
covered by the Employee Plan shall be ineligible to participate.

<PAGE>

                                       -2-

Article 3. Retirement Age.

     The retirement age for a Director of the Company shall be determined as
follows:

<TABLE>
<CAPTION>
                   Position                     Retirement Age
                   --------                     --------------
<S>                                             <C>
President and Representative Director                 68

Vice President and Representative Director            66

Senior Managing Director                              64

Managing Director                                     64

Director (without any of the Above job title)         62
</TABLE>

     A Director shall retire from the Company effective as of the next Ordinary
General Meeting of Shareholders held following the date such Director reaches
the indicated retirement age, provided however, that nothing herein shall be
construed as requiring a Director to retire if the Shareholders request such
Director to extend his retirement age and he is willing and able to do so, and
provided further, that nothing herein shall be construed to prevent a Director
from electing to retire at any time prior to reaching the indicated retirement
age.

Article 4. Senior Advisers.

     A Director who has actually retired shall be eligible for appointment by
the Board of Directors to the position of Senior

<PAGE>

                                       -3-

Adviser of the Company. A Director, if so appointed, shall serve as a Senior
Adviser for a fixed term, as determined in each instance at the time of
appointment. The fixed term may be renewed or extended. A Senior Adviser shall
receive as compensation a monthly payment equal to 60% of his base monthly
remuneration at the time of retirement (the "Senior Adviser Fee") for so long as
he shall serve as a Senior Adviser. Additionally, a Senior Adviser shall receive
reasonable compensation and reimbursement of expenses for any specific
assignments he may be requested to carry out on behalf of the Company. A Senior
Adviser who assumes any office with, and/or is employed by, any other person,
company or legal entity without the prior written consent of the Company shall
cease to be a Senior Adviser and shall receive no further payments hereunder.

Article 5. Retirement Allowance.

     5.01 The retirement allowance of a Director for time served in each of the
following positions shall be computed by multiplying: (i) the Director's base
monthly remuneration at the date of retirement by (ii) the number of years
served in the respective position set forth below, and then further multiplied
by (iii) the respective multiplication factor(s) pertaining to the highest
position(s) held by the Director

<PAGE>

                                       -4-

during the last ten (10) years prior to retirement; provided, however, that the
retirement allowance for years of service in any, or a combination, of the
following positions which are in excess of the last ten years (10) of service
shall be computed by multiplying item (i) above by the number of excess years,
and then further multiplied by the multiplication factor for a Director (1.25):

<TABLE>
<CAPTION>
                   Position                      Factor
                   --------                      ------
<S>                                              <C>
President and Representative Director              3.2
Vice President and Representative Director         2.5
Senior Managing Director                           2.0
Managing Director                                  1.5
Director (without any of the above job titles)    1.25
</TABLE>

     In the event that the Director has held more than one of the above
positions, the total retirement allowance shall be computed by adding the
retirement allowance for each position held as calculated above, subject to the
proviso of the first paragraph of this Article 5.

     For purposes of above calculations, the unit of length of service shall be
180 days. A period of more than 180 days

<PAGE>

                                       -5-

making up part of the length of service shall be considered as a full year, and
any period of service less than 180 days and more than one month shall be
considered as one half of a year.

     In addition to the above, a Director who has rendered service of particular
merit to the Company may be granted a meritorious retirement award of up to 50%
of the retirement allowance calculated above.

     5.02 In addition to the retirement allowance calculated in accordance with
Article 5.01 above, any Director who has served as a Director of the Company for
a period of 20 years or more, of which at least 16 years have been in the
capacity as the President and Representative Director of the Company, shall be
entitled to receive an annual supplemental retirement allowance equal to 40% of
the average of the three highest gross annual base remuneration received from
the Company, including all entities affiliated with the Company, subject to the
following:

     A.   For purposes of this calculation, amounts considered as bonuses or
          incentives shall not be counted as part of the Director's annual base
          remuneration.

<PAGE>

                                       -6-

     B.   The supplemental retirement allowance shall be paid annually in twelve
          equal installments beginning in the month following the month in which
          the Director retires from active service with the Company, provided
          however, that in the event the Director retires before reaching the
          age of 65 the supplemental retirement allowance will not begin until
          the month following the month in which the Director turns 65 years of
          age.

     C.   In the event the Director meets the minimum requirement of having
          served for a period of 16 years as the President and Representative
          Director of the Company but is required to retire from the Company
          before satisfying the requirement of having served as a Director of
          the Company for 20 years either as a result of a permanent disability
          or at the request of the Company or its shareholder for any reason,
          the supplemental retirement allowance shall vest immediately and
          payment shall begin as of the date of separation from the Company.

     D.   The supplemental retirement allowance shall be

<PAGE>

                                       -7-

          paid monthly to the Director (or the Director's legal heirs) for a
          period of 180 months or until the death of the Director, whichever
          comes later.

     E.   In the event the Director dies after serving for 16 years as the
          President and Representative Director of the Company but before
          retirement, the supplemental retirement allowance shall be paid to the
          Director's spouse for up to a maximum of 180 months, provided that if
          at the time of the Director's death, the Director is not survived by a
          spouse or if the surviving spouse dies before the expiration of the
          180-month term, then the remaining months of supplemental retirement
          allowance payments shall be paid to the Director's legal heirs.

Article 6. Death or Permanent Disability.

     In the event a Director dies or becomes permanently disabled prior to his
retirement, his years of service as Director and his retirement allowance shall
be calculated as if he had finished his then current term as a Director. In the
event that a Director dies prior to his retirement, his retirement allowance as
calculated herein, subject to approval

<PAGE>

                                       -8-

by the Shareholders of the Company, and subject to Article 5.02, E Above, shall
be paid to his legal heirs. A Director who dies or becomes permanently disabled
while serving as a Special Adviser shall receive the Special Advisers Fee (in
the case of death it shall be paid to his legal heirs) for a period of six
months after the date of death or permanent disability.

Article 7. Payment.

     Retirement allowance shall be paid within 60 days of the date of the
Shareholders' Meeting at which the Director's term expires. In the case of death
or permanent disability prior to retirement, retirement allowance shall be paid
within 120 days of the date of death or permanent disability.

Article 8. Amendment or Modification.

     This Retirement Allowance Plan may be amended or modified at any time by
the Shareholders of the Company at a duly convened Shareholders' Meeting.EX-10.1

 

Exhibit 10.1

PROSIDION LIMITED

SCIENTIFIC ADVISORY BOARD AND CONSULTING AGREEMENT

     This Scientific Advisory Board and Consulting Agreement (this “Agreement”) is made and entered
into as of February 10, 2006 (“the “Effective Date”) by and between Prosidion Limited, a company
registered in England and Wales under registered number 4600121 with its registered office at
Watlington Road, Oxford, UK OX4 6LT (the “Company”) and Dr Daryl Granner, Professor, an individual
with an address of 707 Light Hall, Vanderbilt University Medical Centre, Nashville, Tennessee
37232, USA (“Consultant”).

Recitals

     The Company desires to retain distinguished physicians as members of the Company’s Scientific
Advisory Board (the “Board”) to advise the Company with respect to new and existing compounds and
products in research and development in the field of diabetes, metabolic diseases and obesity. The
Company and Consultant desire to enter into this Agreement in order to set forth the basis on which
Consultant will serve as a member of the Board and provide consulting services to the Company in
relation thereto.

Agreement

     In consideration of the mutual covenants set forth below, the parties hereby agree as follows:

	 	1.	 	Engagement of Services.

              (a) Consultant shall serve as chairman of the Board and will provide ongoing advice to the
Company with respect to research, development and marketing of diabetes, metabolic diseases and
obesity products. Such services shall be performed as requested by the Company, at such places and
times as shall be mutually agreeable to the Company and Consultant. It is anticipated that the
Board will meet in person on four (4) occasions per year. In addition, Consultant shall be
available to consult with the Company with respect to diabetes, metabolic diseases and obesity
opportunities, over the telephone and in person, as requested by the Company and at mutually
agreeable times and locations. Services performed pursuant to this Agreement shall be performed at
such times as shall not conflict with Consultant’s obligations to Consultant’s primary employer or
other third parties for whom Consultant provides consulting services. Consultant shall have no
minimum consulting obligation hereunder.

              (b) Consultant agrees to perform all services for the Company hereunder faithfully, diligently
and to the best of Consultant’s skill and ability.

              (c) Consultant represents that Consultant has the authority to enter into this Agreement and
that Consultant’s performance of the terms of this Agreement and service as a member of the Board
and a consultant to the Company do not and will not breach any obligation or agreement of
Consultant to Consultant’s primary employer or any other third party.

              (d) Consultant understands and acknowledges that the payments Consultant will receive pursuant
to Section 2 below are intended solely to compensate Consultant for the

OSI-Scientific
Advisory Board 3/2002

 

 

services Consultant will provide hereunder. Such payments shall in no way influence
Consultant’s professional judgment in performing services hereunder or otherwise.

	 	2.	 	Compensation.

              (a) In consideration of Consultant’s services hereunder, the Company shall pay to Consultant a
fee at the rate of seventy five thousand US dollars ($75,000) per annum pro rated for the term of
the Agreement (ie six thousand two hundred and fifty US dollars (US$6,250) per calendar month) on
the understanding that it is anticipated that the Company shall hold approximately four (4) Board
meetings per annum and that ad hoc Board meetings may from time to time be convened. Fees shall be
payable to Consultant on a monthly basis in arrears.

              (b) The Company will reimburse Consultant for travel and other out-of-pocket expenses
reasonably and properly incurred by Consultant in the course of performing services under this
Agreement; provided, however, that Consultant provides the Company with appropriate receipts and
other relevant documentation for all such costs as part of any request by Consultant for
reimbursement. Notwithstanding the foregoing, Consultant shall obtain the prior written consent of
the Company for any expenses that will exceed, in the aggregate, more than $2,500.

              (c) In recognition of Consultant’s services to the SAB during the period 1st
January, 2006 to the Effective Date, the Company shall, in addition to the remuneration detailed in
Section 2(a), pay to Consultant the sum of six thousand two hundred and fifty US dollars (US$6,250)
per calendar month for such interim period, payable within thirty (30) days of the Effective Date.

	 	3.	 	Independent Contractor.

     It is understood and agreed that Consultant is an independent contractor and not an employee
of the Company. Consultant has no authority to obligate the Company by contract or otherwise and
shall in no way represent Consultant to be an employee or officer of the Company. Consultant will
not be eligible for any employee benefits, nor will the Company make deductions from Consultant’s
fees for any taxes, national insurances or VAT payments. Taxes, national insurance and VAT
payments shall be the sole responsibility of Consultant.

	 	4.	 	Additional Activities.

              (a) The Company acknowledges that Consultant has other employment and consulting obligations,
and that these obligations may take priority over the obligations Consultant has to the Company by
reason of this Agreement.

              (b) The Company’s policy is that persons who serve as principal investigators for clinical
trials sponsored by the Company may not hold stock or other equity interests in the Company.
Consultant agrees that if in the future Consultant becomes a principal investigator or otherwise
plays a significant role in any clinical trial sponsored by the Company, Consultant will comply
with this policy.

              (c) In order to avoid conflicts concerning ownership of intellectual property, Consultant will
not conduct work for the Company on the premises of Consultant’s employer or with its facilities
unless there is a written agreement covering such work between the Company and such institution.

OSI-Scientific
Advisory Board 3/2002

2

 

	 	5.	 	Proprietary Information.

              (a) During the course of Consultant’s services hereunder, the Company may disclose, or
Consultant may otherwise have access to, Proprietary Information of the Company. For purposes of
this Agreement, “Proprietary Information” shall mean information relating to the Company’s research
and development programs and results, therapeutic candidates and products, clinical and preclinical
data, Inventions (as defined in Section 7), trade secrets, business strategy, patent rights,
licenses, product and marketing strategy and materials, market data, personnel, consultants,
suppliers, manufacturers, licensors, licensees, partners, affiliates, customers, potential
customers or others, or other matters related to and treated confidentially by the Company.

              (b) Proprietary Information subject to this Section 5 shall not include information that: (i)
is or later becomes available to the public through no breach of this Agreement by Consultant; (ii)
is obtained by Consultant from a third party who had the legal right to disclose the information to
Consultant; (iii) is already in the possession of Consultant on the date this Agreement becomes
effective and was not Proprietary Information or subject to other restrictions on disclosure as of
that date as shown by written records predating the date it was obtained under this Agreement; or
(iv) is required to be disclosed by law, government regulation, or court order, provided that
Consultant gives the Company prompt notice of such disclosure requirement and assists the Company
so as to enable the Company to seek limitations or exemptions from such disclosure requirement.

              (c) Consultant acknowledges that the protection of Proprietary Information is necessary to
conduct the Company’s business, and the Company is and shall at all times remain the sole owner of
the Company’s Proprietary Information.

              (d) During the term of this Agreement and for five (5) years thereafter, Consultant will keep
in confidence and trust all Proprietary Information, and shall not use or disclose such Proprietary
Information, except as such use may be required in performing services as a consultant to the
Company.

	 	6.	 	Nondisclosure of Third-Party Information.

     Consultant understands that the Company has received and in the future will receive from third
parties information that is confidential or proprietary (“Third-Party Information”), subject to a
duty on the part of the Company to maintain the confidentiality of such information and to use it
only for certain limited purposes. During the term of this Agreement and thereafter, Consultant
will hold Third-Party Information which Consultant learns in connection with Consultant’s services
hereunder in the strictest confidence and will not disclose or use such Third-Party Information
except as permitted by the agreement between the Company and such third party, unless expressly
authorized to act otherwise by the Company.

	 	7.	 	Rights to Inventions and Intellectual Property.

              (a) In connection with Consultant’s services hereunder, or by use of the resources of the
Company, Consultant may produce, develop, create or invent Inventions and Intellectual Property
(each as defined below) related to the business of the Company. Consultant shall maintain and
furnish to the Company complete and current records of all such Inventions and Intellectual
Property and disclose to the Company in writing any such Inventions and

OSI-Scientific
Advisory Board 3/2002

3

 

Intellectual Property. Consultant agrees that all such Inventions and Intellectual Property
are and shall be the exclusive property of the Company, and that the Company may use or pursue them
without restriction or additional compensation. Consultant: (i) hereby assigns, sets over and
transfers to the Company all of Consultant’s right, title and interest in and to such Inventions
and Intellectual Property; (ii) agrees that Consultant and Consultant’s agents shall, during and
after the period Consultant is retained by the Company, cooperate fully in obtaining patent,
trademark, service mark, copyright or other proprietary protection for such Inventions and
Intellectual Property, all in the name of the Company (but only at Company expense), and, without
limitation, shall execute all requested applications, assignments and other documents in
furtherance of obtaining such protection or registration and confirming full ownership by the
Company of such Inventions and Intellectual Property; and (iii) shall, upon termination or
expiration of this Agreement, provide to the Company in writing a full, signed statement of all
Inventions and Intellectual Property in which Consultant participated prior to such termination or
expiration.

              (b) For purposes of this Agreement, “Intellectual Property” shall mean any Invention, writing,
trade name, trademark, service mark or any other material registered or otherwise protected or
protectable under state, federal, or foreign patent, trademark, copyright, or similar laws; and
“Inventions” shall mean ideas, discoveries, inventions, developments and improvements, whether or
not reduced to practice and whether or not patentable or otherwise within the definition of
Intellectual Property.

              (c) Consultant acknowledges that the protection of Intellectual Property is necessary to
conduct the Company’s business, and the Company is and shall at all times remain the sole owner of
the Company’s Intellectual Property.

	 	8.	 	Term and Termination.

              (a) This Agreement shall commence on the Effective Date and be effective until 31st
December 2006, unless the Agreement is extended beyond this term by prior written agreement of the
parties; in the absence of which this Agreement and any obligations contained herein or understood
between the parties in relation to membership on the Board and other advisory services shall
forthwith lapse.

              (b) Either party can terminate this Agreement at any time upon sixty (60) days prior notice in
which event this Agreement and any obligations contained herein or understood between the parties
in relation to membership on the Board shall forthwith lapse and only those fees payable to the
date of termination shall be payable by the Company.

              (c) The parties shall mutually agree in writing with respect to any extension of the term
hereof.

	 	9.	 	Effect of Termination.

     Upon the expiration or termination of this Agreement, each party shall be released from all
obligations and liabilities to the other occurring or arising after the date of such expiration or
termination, except that expiration or termination of this Agreement shall not relieve (i)
Consultant of Consultant’s obligations under Sections 5, 6 and 7 hereof; (ii) the Company of its
obligations to reimburse Consultant for expenses under Section 2(b) hereof; or (iii) Consultant or
the Company from any liability arising from any breach of this Agreement. Upon expiration or
termination of this Agreement for any reason whatsoever, Consultant shall promptly surrender and
deliver to the Company all documents and other materials pertaining to Consultant’s work

OSI-Scientific
Advisory Board 3/2002

4

 

with the Company, and any documents or other materials (including reproductions thereof)
containing any Proprietary Information.

	 	10.	 	Assignment.

     The rights and liabilities of the parties hereto shall bind and inure to the benefit of their
respective successors, heirs, executors and administrators, as the case may be; provided, however,
that because the Company has specifically contracted for Consultant’s services, Consultant may not
assign or delegate Consultant’s obligations under this Agreement, either in whole or in part,
without the prior written consent of the Company.

	 	11.	 	Legal and Equitable Remedies.

     Since Consultant’s services are personal and unique and since Consultant may have access to
Proprietary Information, the Company shall have the right to enforce this Agreement and any of its
provisions by injunction, specific performance or other equitable relief without prejudice to any
other rights and remedies that the Company may have for a breach of this Agreement.

	 	12.	 	Governing Law; Severability.

     This Agreement shall be governed by the laws of England and Wales and the parties hereby
submit to the exclusive jurisdiction of the English courts. If any provision of this Agreement is
found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and
the remainder of this Agreement shall continue in full force and effect.

	 	13.	 	Complete Understanding; Modification.

     This Agreement constitutes the final, exclusive and complete understanding and agreement of
the parties hereto and supersedes all prior understandings and agreements. Any waiver,
modification or amendment of any provision of this Agreement shall be effective only if in writing
and signed by the parties hereto.

	 	14.	 	Notices.

              (a) All notices, requests, consents and other communications hereunder shall be in writing,
addressed to the receiving party’s address as set forth below or to such other address as a party
may designate by notice hereunder, and either (i) delivered by hand, (ii) sent by overnight
courier, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid.

              (b) All notices, requests, consents and other communications hereunder shall be deemed to have
been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the
address of such party set forth above, (ii) if sent by overnight courier, on the next business day
following the day such notice is delivered to the courier service, or (iii) if sent by registered
or certified mail, on the third business day following the day such mailing is made.

OSI-Scientific
Advisory Board 3/2002

5

 

	 	15.	 	Counterparts.

     This Agreement may be executed by the parties hereto on separate counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above.

	 	 	 	 	 
	PROSIDION LIMITED

	 	 	 	CONSULTANT
	 
	 	 	 	 
	/s/ Dr. Anker Lundermose

	 	 	 	/s/ Dr. Daryl Granner
	 

	 	 	 	 
	By
Dr. Anker Lundermose

	 	 	 	Dr. Daryl Granner
	CEO
	 	 	 	 

OSI-Scientific
Advisory Board 3/2002

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]